News Center

Home page

Peak Report

News reports

Pro 2012-015 (Jianfeng Group's Announcement on the Resolution of the 6th Session of the 8th Board of Directors)

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2012-015

Zhejiang Jianfeng Group Co., Ltd.

Sixth Board Resolution Announcement

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

On August 24, 2012, Zhejiang Jianfeng Group Co., Ltd. held the 6th meeting of the eighth board of directors by means of correspondence. The company currently has nine directors. The nine directors who participated in the voting complied with the relevant provisions of the "Company Law" and the company's "Articles of Association". The resolutions made were legal and valid. The following resolutions were passed by vote:

1. 2012 Semi-Annual Report

The full text of the company's 2012 semi-annual report was published on the Shanghai Stock Exchange website: http://www.sse.com.cn on the same day, and the summary of the semi-annual report was published in Shanghai Securities News and China Securities Journal "And on the website of Shanghai Stock Exchange.

Voting result: 9 votes in favor, 0 votes against, 0 abstentions.

2. Proposal on Amending the Company's Articles of Association

In order to improve the decision-making procedures and mechanisms for the company's profit distribution matters, form a scientific, continuous and stable dividend policy, and actively return investors, according to the Company Law, Securities Law and other relevant laws and regulations, in accordance with the China Securities Regulatory Commission's "Notice on Further Implementing Matters Related to Cash Dividends of Listed Companies" ( Securities Regulatory Commission [2012 ] 37 Document ) and the China Securities Regulatory Commission's "Notice on Forwarding Matters Related to Further Implementing Cash Dividends of Listed Companies" ( Zhejiang Securities Regulatory Commission Listing Word [2012 ] 138 ) requirements. The articles of association of the company are amended as follows:

the revision comparison table of the articles of association of the company

after the original articles of association

are revised:

Article 77 The following matters shall be passed by the shareholders' general meeting by special resolution:

(I) the company to increase or decrease its registered capital;

(II) the division, merger, dissolution and liquidation of the company;

(III) the amendment of this Articles of Association;

(IV) that the company purchases or sells major assets within one year or the amount of guarantee exceeds the company's latest audited total assets 30% ;

(V) equity incentive plan;

(VI) the provisions of laws, administrative regulations or these articles of association, and other matters that the general meeting of shareholders determines by ordinary resolution to have a significant impact on the company and require a special resolution.

Article 77 The following matters shall be passed by the shareholders' general meeting by special resolution:

(I) the company to increase or decrease its registered capital;

(II) the division, merger, dissolution and liquidation of the company;

(III) the amendment of these articles of association;

(IV) the company to purchase or sell major assets or guarantee amount exceeding 30% of the company's latest audited total assets within one year;

(V) equity incentive plan;

(VI) Revise the Company's Cash Dividend Policy;

( 7 ) laws, administrative regulations or this Articles of Association, and other matters that the general meeting of shareholders determines by ordinary resolution that will have a significant impact on the company and need to be passed by special resolution.

The original Articles of Association

Article 154 the company to implement an active profit distribution policy.

(I) can distribute dividends in cash or stock;

The board of directors of (II) companies can make mid-term distributions based on actual operating conditions. Unless due to special reasons (such as major asset restructuring, etc.), the company will not distribute profits in other periods except annual and medium-term distribution;

(III) that the accumulated profits distributed by the company in cash in the past three years shall not be less than the 30% of the annual average distributable profits realized in the past three years;

The profit distribution of (IV) companies shall not exceed the scope of accumulated distributable profits;

(V) After the company's general meeting of shareholders has made a resolution on the profit distribution plan, the company's board of directors must complete the distribution of dividends (or shares) within 2 months after the general meeting of shareholders.

After revision:

Article 154 The company's profit distribution policy is:

(I) the company's profit distribution principle: The company should attach importance to reasonable returns to investors, adhere to the company's sustainable development, and the profit distribution policy should maintain continuity and stability.

(II) the decision-making procedure and mechanism of the company's profit distribution: the board of directors shall draw up a profit distribution plan according to the company's operating conditions and submit it to the general meeting of shareholders for deliberation and decision. When formulating and reviewing the profit distribution plan, the independent directors shall express their opinions, and the company shall communicate and communicate with shareholders, especially small and medium shareholders, through various channels (including but not limited to telephone, fax and email communication, etc.), and fully listen to the opinions and demands of small and medium shareholders.

(III) profit distribution form: The company may distribute profits in cash, stock, a combination of cash and stock, or other forms permitted by laws and regulations.

Specific conditions for (IV) cash dividends:

( 1 ) The company realizes annual profit and the undistributed profit is positive;

( 2 ) The audit institution issued a standard unqualified audit report on the company's annual financial report;

( 3 ) The company has no major investment plan or major cash expenditure plan, and the company's cash flow can meet the company's normal operation and sustainable development.

(V) the conditions for the issuance of stock dividends: When the company is in good business conditions, and the board of directors believes that the company's stock price does not match the company's share capital scale, and the issuance of stock dividends is beneficial to the overall interests of all shareholders of the company, it can meet the above-mentioned cash Dividends Under the conditions, a stock dividend distribution plan is proposed.

(VI) the proportion of cash dividends: the company's accumulated profits distributed in cash in the past three years are not less than 30% of the average annual distributable profits realized in the past three years.

Time interval for (VII) profit distribution: When the conditions stipulated in this Articles of Association are met, the company can make profit distribution once a year, and the company's board of directors can also propose the company to make interim profit distribution based on the company's profitability and cash flow. The Company does not distribute profits for periods other than annual and interim distributions except for special reasons (e. g., major asset restructuring, etc.).

(VIII) Other

( 1 ) Where a shareholder illegally occupies the company's funds, the company shall deduct the cash dividends distributed by the shareholder to repay the funds occupied by him.

( 2 ) The company's profit distribution shall not exceed the range of undistributed profits and shall not impair the company's ability to continue operations.

( 3 ) After the general meeting of shareholders of the company makes a resolution on the profit distribution plan, the board of directors of the company shall complete the distribution of dividends (or shares) within 2 months after the resolution of the general meeting of shareholders is 231.

( 4 ) If the company's annual profit and undistributed profit is positive, and the company's board of directors has not made a cash dividend distribution plan, the independent directors shall express their independent opinions on this. The company shall disclose in its periodic reports the reasons for not paying dividends and the purpose for which the funds not used for dividends are retained in the company.

The proposal will be submitted to the shareholders' meeting for deliberation.

voting result: 9 votes in favor, 0 votes against and 0 abstentions.

Proposal of the 3. on the Company's "Shareholder Return Plan for the Next Three Years (2012-2014)"

For the full text, please refer to the "Shareholder Return Plan of Zhejiang Jianfeng Group Co., Ltd. for the Next Three Years (2012-2014)" published on the website http://www.sse.com.cn of Shanghai Stock Exchange on August 28, 2012.

The motion will be submitted to the shareholders' meeting for consideration.

voting result: 9 votes in favor, 0 votes against and 0 abstentions.

Proposal of 4. on Adjusting Jinxi Project of Jianfeng Pharmaceutical

The 19th Session of the 7th Board of Directors of the Company held on April 8, 2011 reviewed and approved Jinxi Project of Jianfeng Pharmaceutical. Jianfeng Pharmaceutical plans to invest and build a production base in Jinxi Development Zone of Jinhua City. The project name is: annual output of 35 tons of cephalosporins, anti-tumor drugs and other raw materials and 2 .1 billion kinds of various kinds,# The total investment of the 272 project is 479.69 million yuan . For details, please refer to "china securities journal", "shanghai securities news" and the website of Shanghai Stock Exchange (http://www.sse.com.cn ) "Zhejiang Jianfeng Group Co., Ltd. Major Project Investment Announcement" (Pro 2011-009) on April 12, 2011.

After deliberation by the board of directors, it is agreed that the subsidiary Jianfeng Pharmaceutical Co., Ltd. will adjust the construction content of Jinxi Project. After filing by Jinhua Economic and Information Committee, the project name of Jinxi Project (Phase I) is "Technical Transformation Project of 35 tons of Cephalosporins, Antitumor Drugs and Other Raw Material Drug Production Lines and Supporting Various Preparation Production Lines". The first phase of

items items total investment is 53180.07 .84 million yuan , of which fixed investment 48614.46 .88 million yuan and basic working capital 4565.61 .9 million yuan.

voting result: 9 votes in favor, 0 votes against and 0 abstentions.

Proposal of the 5. on Convening the First Extraordinary General Meeting of Shareholders in 2012

Decided to Convene the First Extraordinary General Meeting of Shareholders in 2012 on September 12, 2012 (Wednesday). For details, please refer to the "Notice on Convening the First Extraordinary General Meeting of Shareholders in 2012"

Voting Results: 9 votes in favor, 0 votes against and 0 abstentions.

hereby announce

August 28, 2012

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页